FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3032362009> ?p ?o ?g. }

• W3032362009 abstract "In current management of type 2 diabetes (T2DM), cardiovascular and renal prevention have become important targets to be achieved. In this context, a joint panel of four endocrinology societies from Brazil and Portugal was established to develop an evidence-based guideline for treatment of hyperglycemia in T2DM.MEDLINE (via PubMed) was searched for randomized clinical trials, meta-analyses, and observational studies related to diabetes treatment. When there was insufficient high-quality evidence, expert opinion was sought. Updated positions on treatment of T2DM patients with heart failure (HF), atherosclerotic CV disease (ASCVD), chronic kidney disease (CKD), and patients with no vascular complications were developed. The degree of recommendation and the level of evidence were determined using predefined criteria.In non-pregnant adults, the recommended HbA1c target is below 7%. Higher levels are recommended in frail older adults and patients at higher risk of hypoglycemia. Lifestyle modification is recommended at all phases of treatment. Metformin is the first choice when HbA1c is 6.5-7.5%. When HbA1c is 7.5-9.0%, dual therapy with metformin plus an SGLT2i and/or GLP-1RA (first-line antidiabetic agents, AD1) is recommended due to cardiovascular and renal benefits. If an AD1 is unaffordable, other antidiabetic drugs (AD) may be used. Triple or quadruple therapy should be considered when HbA1c remains above target. In patients with clinical or subclinical atherosclerosis, the combination of one AD1 plus metformin is the recommended first-line therapy to reduce cardiovascular events and improve blood glucose control. In stable heart failure with low ejection fraction (< 40%) and glomerular filtration rate (eGFR) > 30 mL/min/1.73 m2, metformin plus an SGLT-2i is recommended to reduce cardiovascular mortality and heart failure hospitalizations and improve blood glucose control. In patients with diabetes-associated chronic kidney disease (CKD) (eGFR 30-60 mL/min/1.73 m2 or eGFR 30-90 mL/min/1.73 m2 with albuminuria > 30 mg/g), the combination of metformin and an SGLT2i is recommended to attenuate loss of renal function, reduce albuminuria and improve blood glucose control. In patients with severe renal failure, insulin-based therapy is recommended to improve blood glucose control. Alternatively, GLP-1RA, DPP4i, gliclazide MR and pioglitazone may be considered to reduce albuminuria. In conclusion, the current evidence supports individualizing anti-hyperglycemic treatment for T2DM." @default.
• W3032362009 created "2020-06-05" @default.
• W3032362009 creator A5000471932 @default.
• W3032362009 creator A5002292435 @default.
• W3032362009 creator A5005845648 @default.
• W3032362009 creator A5011058924 @default.
• W3032362009 creator A5013601808 @default.
• W3032362009 creator A5015960003 @default.
• W3032362009 creator A5022698010 @default.
• W3032362009 creator A5023269134 @default.
• W3032362009 creator A5025265502 @default.
• W3032362009 creator A5025832509 @default.
• W3032362009 creator A5029927592 @default.
• W3032362009 creator A5033028210 @default.
• W3032362009 creator A5034621392 @default.
• W3032362009 creator A5035210673 @default.
• W3032362009 creator A5035992971 @default.
• W3032362009 creator A5038406759 @default.
• W3032362009 creator A5039372939 @default.
• W3032362009 creator A5041440438 @default.
• W3032362009 creator A5042568313 @default.
• W3032362009 creator A5044577316 @default.
• W3032362009 creator A5045656241 @default.
• W3032362009 creator A5053238009 @default.
• W3032362009 creator A5055891634 @default.
• W3032362009 creator A5056486220 @default.
• W3032362009 creator A5056660108 @default.
• W3032362009 creator A5058012518 @default.
• W3032362009 creator A5058428004 @default.
• W3032362009 creator A5058539058 @default.
• W3032362009 creator A5071766118 @default.
• W3032362009 creator A5077792678 @default.
• W3032362009 creator A5086192039 @default.
• W3032362009 creator A5088934589 @default.
• W3032362009 creator A5089426997 @default.
• W3032362009 date "2020-05-24" @default.
• W3032362009 modified "2023-10-18" @default.
• W3032362009 title "Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus" @default.
• W3032362009 cites W1489159393 @default.
• W3032362009 cites W1526927233 @default.
• W3032362009 cites W1752045965 @default.
• W3032362009 cites W1846464686 @default.
• W3032362009 cites W1861139520 @default.
• W3032362009 cites W1976425553 @default.
• W3032362009 cites W2013253832 @default.
• W3032362009 cites W2022921728 @default.
• W3032362009 cites W2026963340 @default.
• W3032362009 cites W2046335747 @default.
• W3032362009 cites W2060716197 @default.
• W3032362009 cites W2064130493 @default.
• W3032362009 cites W2075182875 @default.
• W3032362009 cites W2095436610 @default.
• W3032362009 cites W2102076191 @default.
• W3032362009 cites W2105407506 @default.
• W3032362009 cites W2105575861 @default.
• W3032362009 cites W2108453323 @default.
• W3032362009 cites W2109682339 @default.
• W3032362009 cites W2125028944 @default.
• W3032362009 cites W2127854619 @default.
• W3032362009 cites W2134652590 @default.
• W3032362009 cites W2142830692 @default.
• W3032362009 cites W2144325462 @default.
• W3032362009 cites W2146264128 @default.
• W3032362009 cites W2148367662 @default.
• W3032362009 cites W2158323596 @default.
• W3032362009 cites W2159969745 @default.
• W3032362009 cites W2167639134 @default.
• W3032362009 cites W2171294019 @default.
• W3032362009 cites W2172035122 @default.
• W3032362009 cites W2188846692 @default.
• W3032362009 cites W2205010449 @default.
• W3032362009 cites W2271771390 @default.
• W3032362009 cites W2302447233 @default.
• W3032362009 cites W2337454357 @default.
• W3032362009 cites W2341376576 @default.
• W3032362009 cites W2425644022 @default.
• W3032362009 cites W2514337428 @default.
• W3032362009 cites W2519510391 @default.
• W3032362009 cites W2519803668 @default.
• W3032362009 cites W2534221266 @default.
• W3032362009 cites W2559748650 @default.
• W3032362009 cites W2611137524 @default.
• W3032362009 cites W2626446274 @default.
• W3032362009 cites W2734525258 @default.
• W3032362009 cites W2752707491 @default.
• W3032362009 cites W2754041380 @default.
• W3032362009 cites W2755083612 @default.
• W3032362009 cites W2769264260 @default.
• W3032362009 cites W2780874826 @default.
• W3032362009 cites W2788154323 @default.
• W3032362009 cites W2790320081 @default.
• W3032362009 cites W2802245520 @default.
• W3032362009 cites W2808008353 @default.
• W3032362009 cites W2884052378 @default.
• W3032362009 cites W2884113191 @default.
• W3032362009 cites W2889345352 @default.
• W3032362009 cites W2899404570 @default.
• W3032362009 cites W2899764361 @default.
• W3032362009 cites W2900149048 @default.
• W3032362009 cites W2900413769 @default.

• next